BRAIN and NERVE－神経研究の進歩73巻6号

2021年06月発行

総説

PETによる抗うつ薬のモノアミントランスポーター占有率に関する研究—セロトニン／ノルエピネフリントランスポーターを中心に

著者： 松山敏¹ 荒川亮介² 浅見優子¹

所属機関： ¹ファイザー株式会社アップジョン事業部門メディカル・アフェアーズ統括部 ²日本医科大学精神医学教室

ページ範囲：P.731 - P.736

文献概要

ポジトロンエミッション断層撮影法（PET）により，抗うつ薬の脳内モノアミントランスポーター占有率を測定できる。従来，臨床的に抗うつ効果を得るために必要なセロトニントランスポーター（SERT）占有率は80％とされてきた。一方，ノルエピネフリントランスポーター（NET）占有率の報告は増えているものの，抗うつ効果を得るためのNET占有率を単独で推定することは難しい。 今後，理想的なSERTとNETの占有率の比率やNET阻害の意義についての研究が求められる。

参考文献

1）渡邊衡一郎: 変わりゆくうつ病の薬物療法. 精神経誌112: 1105-1114, 2010

2）Takano A, Suzuki K, Kosaka J, Ota M, Nozaki S, et al: A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 185: 395-399, 2006

3）Arakawa R, Takano A, Halldin C: PET technology for drug development in psychiatry. Neuropsychopharmacol Rep 40: 114-121, 2020

. Int J Neuropsychopharmacol 22: 278-285, 2019

. Int J Neuropsychopharmacol 16: 937-943, 2013

. Int J Neuropsychopharmacol 20: 957-962, 2017

C]DASB PET imaging study. Am J Psychiatry 158: 1843-1849, 2001

C]-DASB binding to the human serotonin transporter: modeling strategies. J Cereb Blood Flow Metab 21: 1342-1353, 2001

C]DASB positron emission tomography study. Am J Psychiatry 161: 826-835, 2004

10）Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, et al: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60: 386-391, 2003

11）Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, et al: Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 45: 935-944, 2003

12）Nutt DJ: The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 67(suppl 6): 3-8, 2006

13）Schildkraut JJ: The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 122: 509-522, 1965

14）Moret C, Briley M: The importance of norepinephrine in depression. Neuropsychiatr Dis Treat 7(Suppl 1): 9-13, 2011

15）Schou M, Halldin C, Sóvágó J, Pike VW, Hall H, et al: PET evaluation of novel radiofluorinated reboxetine analogs as norepinephrine transporter probes in the monkey brain. Synapse 53: 57-67, 2004

. J Nucl Med 49: 1270-1276, 2008

17）Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151 737-748, 2007

. Psychopharmacology (Berl) 210: 331-336, 2010

. Int J Neuropsychopharmacol 17: 553-560, 2014

20）Fric M, Pfuhlmann B, Laux G, Riederer P, Distler G, et al: The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry 41: 151-155, 2008

C]DASB. Eur J Nucl Med 27: 1719-1722, 2000

22）Takano A, Suhara T, Ichimiya T, Yasuno F, Suzuki K: Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. J Clin Psychopharmacol 26: 188-191, 2006

23）Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, et al: AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 44: 195-235, 2011

24）Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, et al: Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391: 1357-1366, 2018

25）Ledbetter M: Atomoxetine: a novel treatment for child and adult ADHD. Neuropsychiatr Dis Treat 2: 455-466, 2006

26）Montoya A, Bruins R, Katzman MA, Blier P: The noradrenergic paradox: implications in the management of depression and anxiety. Neuropsychiatr Dis Treat 12: 541-557, 2016

27）Papakostas GI, Fava M, Thase ME: Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry 63: 699-704, 2008

28）Perahia DGS, Quail D, Desaiah D, Corruble E, Fava M: Switching to duloxetine from selective serotonin reuptake inhibitor antidepressants: a multicenter trial comparing 2 switching techniques. J Clin Psychiatry 69: 95-105, 2008